Hem › Magsäckscancer › Michigan › Detroit
Kliniska studier för Magsäckscancer i Detroit, MI
16 studier för Magsäckscancer söker deltagare vid platser i och runt Detroit (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekryterarFriska volontärer välkomna
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
RekryterarFriska volontärer välkomna
- Henry Ford Health Saint John Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekryterarObservationsstudieFriska volontärer välkomna
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
RekryterarFas 3
- Henry Ford Health, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekryterarFas 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekryterarFas 1
- Barbara Ann Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekryterarFas 1
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekryterarFas 1
- Henry Ford Cancer Institute, Detroit
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekryterarFas 1/2
- Brigitte Harris Cancer Pavilion BHCP, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- Karmanos Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekryterarFas 1/2
- Henry Ford Cancer Institute, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RekryterarFas 1
- Investigative Site #120, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekryterarFas 1
- Karmanos Cancer Institute, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RekryterarFas 1
- Henry Ford Health System, Detroit
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
RekryterarFas 1
- Henry Ford Cancer-Detroit, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RekryterarFas 1/2
- Karmanos Cancer Institute, Detroit
Magsäckscancer-studier i andra städer
- Houston, TX42 studier
- Boston, MA32 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Baldwin Park, CA22 studier
- Los Angeles, CA22 studier
- Arlington, VA20 studier
- Dallas, TX19 studier
- San Antonio, TX19 studier
- St. Louis, MO18 studier
- Grand Rapids, MI18 studier
- Washington, DC16 studier
Andra studier i Detroit
- Icke-småcellig lungcancer44 studier
- Bröstcancer33 studier
- Cancer (alla typer)29 studier
- Kolorektal cancer26 studier
- Äggstockscancer26 studier
- Metastaserande cancer24 studier
- Prostatacancer22 studier
- Endometriecancer21 studier
- Lungcancer20 studier
- Multipelt myelom19 studier
- Plattenepitelcancer i huvud och hals15 studier
- Akut myeloid leukemi14 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.